MINNEAPOLIS, Dec. 6, 2023 /PRNewswire/ -- Pioneer Management Consulting announced today the launch of Pioneer Ventures Group, a new investment arm focused on funding companies researching cures for a rare and lethal pediatric brain cancer, known medically as diffused intrinsic pontine gliomas (DIPG) with H3K27 and EFGR variants.

明尼阿波利斯，2023年12月6日/PRNewswire/--先锋管理咨询公司今天宣布成立先锋风险投资集团，这是一家新的投资机构，专注于资助公司研究罕见致命的小儿脑癌的治疗方法，医学上称为H3K27和EFGR变异的弥漫性固有桥脑胶质瘤（DIPG）。

The fund will eventually expand further into biotech and beyond..

该基金最终将进一步扩展到生物技术及其他领域。。

'We've been working to start a venture arm for more than five years now,' said Pioneer founder and co-owner, Brian Westerhaus. 'We chose to support DIPG research in honor of Molly Koenen's brother, Timothy Orth, and niece, Josephine (Zoey) Orth, who both lost their lives to DIPG at the ages of 18 and 3.' (Koenen is a partner and co-owner at Pioneer Management Consulting and Pioneer Ventures Group.).

先锋创始人兼共同所有人布赖恩·韦斯特豪斯（BrianWesterhaus）说，我们已经努力成立一家风险投资机构五年多了我们选择支持DIPG研究，以纪念Molly Koenen的兄弟Timothy Orth和侄女Josephine（Zoey）Orth，他们都在18岁和3岁时死于DIPG。”（Koenen是Pioneer Management Consulting和Pioneer Ventures Group的合伙人和共同所有者）。

Westerhaus highlighted another challenge that compelled Pioneer to help. 'Unfortunately, pediatric cancer research is woefully underfunded. It gets less than 4% of all cancer research dollars available, and almost none of that goes to rare types, like DIPG. Which means the treatment protocol in 1997 when Tim died, and in 2022, when Zoey was sick, are the same—steroids, radiation, and chemotherapy, all in the desperate hope that they'll buy enough time to get to a miracle clinical trial.

韦斯特豪斯（Westerhaus）强调了另一个迫使先锋公司提供帮助的挑战不幸的是，儿科癌症研究资金严重不足。它获得的癌症研究资金不到所有可用资金的4%，几乎没有一种用于像DIPG这样的罕见类型。这意味着1997年蒂姆去世时的治疗方案和2022年佐伊生病时的治疗方案都是相同的类固醇，放疗和化疗，所有这些都迫切希望他们能争取足够的时间进行奇迹般的临床试验。

And yet, 25 years apart, both died within months of diagnosis.'.

然而，相隔25年，两人都在诊断后的几个月内死亡。”。

The Pioneer Venture Group's first investment is in OX2 Therapeutics (OX2), a company led by Jeff Liter, an experienced biotech executive, and his business partners, Michael Olin, PhD, and Chris Moertel, MD. Olin and Moertel are two leading DIPG researchers in the Department of Pediatrics at the University of Minnesota..

先锋创业集团的第一笔投资是OX2 Therapeutics（OX2），这是一家由经验丰富的生物技术高管杰夫·利尔（Jeff Liter）及其商业合作伙伴迈克尔·奥林（Michael Olin）博士和克里斯·莫特尔（Chris Moertel）博士领导的公司。奥林（Olin）和莫特尔（Moertel）是明尼苏达大学儿科的两位领先的DIPG研究人员。。

OX2 is a leader in the game-changing world of immunotherapies. In simple terms, immunotherapy turns the cancer patient's immune system back on to 'undisguise' and then kill cancer cells, while leaving the body's 'good' cells safe and intact. OX2's approach, called CD200, is catching the attention of the biotech world because of its unique ability to shut down the checkpoints in cancer cells that cause mutation, while also restarting the immune systems to kill them.

OX2是改变游戏规则的免疫疗法领域的领导者。简单地说，免疫疗法将癌症患者的免疫系统重新“公开”，然后杀死癌细胞，同时使身体的“好”细胞安全完整。OX2的方法称为CD200，由于其独特的能力，可以关闭导致突变的癌细胞的检查点，同时重新启动免疫系统杀死它们，因此引起了生物技术界的关注。

A one-of-a-kind dual approach..

一种独一无二的双重方法。。

OX2 completed a trial for adults with high-grade glioblastomas (the equivalent of the pediatric version) at the University of Minnesota with a success rate promising enough to earn the right to start a pediatric trial. The pediatric trial will start in January 2024 at Children's Hospital in Minneapolis, Minnesota.

OX2在明尼苏达大学完成了一项针对成人高级别胶质母细胞瘤（相当于儿科版本）的试验，成功率足以赢得开始儿科试验的权利。儿科试验将于2024年1月在明尼苏达州明尼阿波利斯儿童医院开始。

The company plans to treat and care for 12 to 18 children in the hopes of getting FDA approval to help many, many more..

该公司计划治疗和护理12至18名儿童，希望获得FDA批准，以帮助更多人。。

'My brother, Mike Orth, and his wife, Heather, spent almost 4 months fighting for the life of their daughter, Zoey. Our family spent 14 months fighting for my brother, Tim. In both instances, the communities that surrounded us and the companies we worked for provided immeasurable, comprehensive, and unconditional help.

“我的兄弟迈克·奥思（MikeOrth）和他的妻子希瑟（Heather）花了近4个月的时间为女儿佐伊（Zoey）的生命而战。我们一家花了14个月的时间为我哥哥蒂姆而战。在这两种情况下，我们周围的社区和我们工作的公司都提供了不可估量的、全面的和无条件的帮助。

My goal in life is to pay that forward.'.

我的人生目标就是向前迈进。”。

Please note, clinical trials are funded only by the generosity of those who care. To donate to the pediatric trial at Children's Hospital in Minnesota, please contact Teri Cannon [email protected]

请注意，临床试验仅由关心者的慷慨资助。要向明尼苏达州儿童医院的儿科试验捐款，请联系Teri Cannon[受电子邮件保护]

About Pioneer Management ConsultingPioneer Management Consulting was founded in 2009 and has quickly emerged as one of the fastest-growing consulting firms in the Midwest. The firm has appeared on the Inc. 5000 list of America's fastest-growing private companies for the past two years and currently has offices in Minneapolis and Denver.

关于先锋管理咨询先锋管理咨询成立于2009年，并迅速成为中西部发展最快的咨询公司之一。在过去两年中，该公司已被列入Inc.5000美国增长最快的私营公司名单，目前在明尼阿波利斯和丹佛设有办事处。

Pioneer specializes in guiding complex transformation projects for enterprises, with services spanning strategy, execution, organizational effectiveness, and data analytics..

Pioneer专门为企业指导复杂的转型项目，提供跨越战略、执行、组织有效性和数据分析的服务。。

Media ContactMolly Koenen, Partner and Owner[email protected]Cell: (763) 331-1845

媒体联系人Molly Koenen，合伙人兼所有者[电子邮件保护]手机：（763）331-1845

SOURCE Pioneer Management Consulting

SOURCE Pioneer管理咨询